Avedro Welcomes David J. McIntyre to its Board of Directors
27 March 2015 - 3:01PM
Business Wire
Avedro Inc., a Boston-based ophthalmic pharmaceutical and
medical device company announces today that David J. McIntyre is
joining its Board of Directors. McIntyre currently serves as
Partner for Apple Tree Partners, a healthcare venture capital firm
where he oversees operations of fund finances and medical device
investments.
“I am excited to join the Board at such a pivotal time for the
company and look forward to working with the team as Avedro
continues to drive its market growth,” said McIntyre.
Prior to Apple Tree Partners, McIntyre served as Executive Vice
President, Chief Financial Officer and Chief Operating Officer for
HeartWare International, Inc. (NASDAQ: HTWR), where he oversaw the
medical device company’s global financial and operational efforts.
He previously practiced as a senior attorney specializing in
corporate, mergers and acquisitions, and equity capital markets law
for both Baker & McKenzie and KPMG. McIntyre has also held
various senior financial roles for multinational companies,
including Coal & Allied Industries Ltd., a publicly traded
subsidiary of Rio Tinto. McIntyre holds an MBA (Fuqua Scholar) from
Duke University, a Bachelor of Law from the University of Sydney
(Australia) and a Bachelor of Economics in Accounting from the
University of Technology, Sydney (Australia). He is also a
Certified Practicing Accountant (Australia) and a Legal
Practitioner of the Supreme Court of New South Wales.
“Avedro is thrilled to welcome David to the team and I look
forward to working with him as we look to expand the global
geographic footprint for our corneal cross-linking platform of
pharmaceuticals and technologies,” said David Muller, PhD,
President and Chief Executive Officer for Avedro.
About Avedro, Inc.
Avedro is a privately held pharmaceutical and medical device
company advancing the science and technology of corneal cross
linking and refractive correction.
Avedro distributes its products in various countries outside of
the United States through a network of ophthalmic medical device
distributors. Avedro’s CE Marked products include capital equipment
such as the UV-X devices, the KXL® and KXL II™ Systems, and related
proprietary pharmaceuticals such as the VibeX® and MedioCROSS®
formulations. These systems and products are used in a variety of
treatments including accelerated cross linking for keratoconus,
Lasik Xtra® and PiXL™. Avedro’s KXL System and pharmaceuticals are
being used in an open-label study involving 83 KXL Systems placed
in U.S. clinical sites. Avedro products are not approved for sale
in the United States.
Avedro, Inc.David Iannetta, 781-768-3400diannetta@avedro.com